Delving into the Latest Updates on PR1P with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms-

Target

VEGF

Mechanism

VEGF inhibitors(Vascular endothelial growth factor inhibitors)

Therapeutic Areas

Immune System DiseasesDigestive System DisordersRespiratory Diseases+ [1]

Active Indication

Acute Lung InjuryColitis, Ulcerative

Inactive Indication-

Originator Organization

Orpheus Bioscience, Inc.BOSTON CHILDREN'S HEALTH PHYSICIANS, LLP

Active Organization

Orpheus Bioscience, Inc.BOSTON CHILDREN'S HEALTH PHYSICIANS, LLP

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Severe burns are one of the most devastating injuries, in which sustained inflammation and ischemia often delay the healing process. Pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) have been widely studied for promoting wound healing. However, the short half-life and instability of VEGF limit its clinical applications. In this study, we develop a photo-crosslinked hydrogel wound dressing from methacrylate hyaluronic acid (MeHA) bonded with a pro-angiogenic prominin-1-binding peptide (PR1P). The materials were extruded in wound bed and in situ formed a wound dressing via exposure to short-time ultraviolet radiation. The study shows that the PR1P-bonded hydrogel significantly improves VEGF recruitment, tubular formation, and cell migration in vitro. Swelling, Scanning Electron Microscope, and mechanical tests indicate the peptide does not affect the overall mechanical and physical properties of the hydrogels. For in vivo studies, the PR1P-bonded hydrogel dressing enhances neovascularization and accelerates wound closure in both deep second-degree burn and full-thickness excisional wound models. The Western blot assay shows such benefits can be related to the activation of the VEGF–Akt signaling pathway. These results suggest this photo-crosslinked hydrogel dressing efficiently promotes VEGF recruitment and angiogenesis in skin regeneration, indicating its potential for clinical applications in wound healing.

100 Deals associated with PR1P

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lung Injury	Preclinical	US	Orpheus Bioscience, Inc.	28 Apr 2023
Acute Lung Injury	Preclinical	US	BOSTON CHILDREN'S HEALTH PHYSICIANS, LLP	28 Apr 2023
Colitis, Ulcerative	Preclinical	US	BOSTON CHILDREN'S HEALTH PHYSICIANS, LLP	28 Apr 2023
Colitis, Ulcerative	Preclinical	US	Orpheus Bioscience, Inc.	28 Apr 2023